Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in Upcoming June Investor Conferences

Thursday, May 30, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. will participate in upcoming investor conferences in June 2024. The company is known for its innovative ARCUS platform, which enables sophisticated gene editing therapies, including gene elimination, insertion, and excision. This participation highlights the company's commitment to advancing its gene editing technologies.
Price reaction · baseline $12.27 (2024-05-29 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is participating in investor conferences.
  • The company is utilizing a novel proprietary ARCUS platform.
  • Focus on developing advanced gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 30, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is Precision BioSciences known for?

Precision BioSciences is known for its advanced gene editing technologies using the ARCUS platform.

When will Precision BioSciences participate in investor conferences?

Precision BioSciences will participate in upcoming investor conferences in June 2024.

What does the ARCUS platform do?

The ARCUS platform enables sophisticated gene editing therapies, including gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform investor conferences
Last updated: May 30, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →